ACR适宜性标准:跨性别者乳腺癌筛查
该指南针对跨性别及性别不认同者的乳腺癌筛查,指出筛查建议应基于出生时指定性别、危险因素和外源性激素使用。由于缺乏纵向研究评估筛查效力,现有证据来自顺性别研究外推及有限队列和病例报告。ACR适宜性标准采用RAND/UCLA适宜性方法和GRADE对影像检查适宜性进行评级,证据不足时专家意见可补充。
要点
- 筛查建议基于出生时指定性别、危险因素及外源性激素使用。
- 跨性别者激素治疗下乳腺癌风险与出生性别对照相比高低尚不明确。
- 尚无评估跨性别人群乳腺癌筛查效力的纵向研究。
核心结论
- 跨性别者乳腺癌筛查建议基于出生时指定性别、危险因素和外源性激素使用。
- 跨性别者接受激素治疗后的乳腺癌总体风险较出生性别对照是更低、相当还是更高,现有证据不足以确定。
- 尚无纵向研究评估跨性别人群乳腺癌筛查的效力。
- 现有证据基于从顺性别研究外推的数据以及有限数量的跨性别社区队列研究和病例报告。
研究设计与样本
- 美国放射学会适宜性标准,针对特定临床情况的循证指南,由多学科专家组每年审阅。
- 指南制定与修订包括对同行评审期刊当前医学文献的广泛分析,并应用RAND/UCLA适宜性方法和GRADE对特定临床场景的影像与治疗程序适宜性进行评级。
- 证据缺乏或模棱两可时,专家意见可补充现有证据以推荐影像检查或治疗。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 现有证据不足以确定跨性别者接受激素治疗后的乳腺癌总体风险较出生性别对照是更低、相当还是更高。
- 尚无纵向研究评估跨性别人群乳腺癌筛查的效力。
- 现有证据基于从顺性别研究外推的数据以及有限数量的跨性别社区队列研究和病例报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Breast cancer screening recommendations for transgender and gender nonconforming individuals are based on the sex assigned at birth, risk factors, and use of exogenous hormones. Insufficient evidence exists to determine whether transgender people undergoing hormone therapy have an overall lower, average, or higher risk of developing breast cancer compared to birth-sex controls. Furthermore, there are no longitudinal studies evaluating the efficacy of breast cancer screening in the transgender population. In the absence of definitive data, current evidence is based on data extrapolated from cisgender studies and a limited number of cohort studies and case reports published on the transgender community. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
引用
- Brown A, Lourenco AP, Niell BL, et al. ACR Appropriateness Criteria® Transgender Breast Cancer Screening. J Am Coll Radiol. 2021. PMID: 34794604. doi:10.1016/j.jacr.2021.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。